Trials / Completed
CompletedNCT04539834
Electrolyte State in Patients With COVID-19
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 983 (actual)
- Sponsor
- Zagazig University · Other Government
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Initial case reports and cohort studies have described many clinical characteristics of patients with coronavirus disease 2019 (COVID-19), an emerging infectious disorder caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In early COVID-19 studies, some evidence has been provided that electrolyte disorders may also be present upon patients' presentation, including sodium, potassium, chloride and calcium abnormalities the aim of the study is Identification of elements that affect COVID-19 pathology to improve survival and decrease mortality rate.
Detailed description
SARS-CoV-2 invades human cells through binding angiotensin I converting enzyme 2 (ACE2) on the cell membrane. ACE2 is widely distributed in many types of human tissues, especially in the vital organs, such as heart, liver, kidney, and lungs. ACE2 is viewed as the principal counter-regulatory mechanism for the main axis of renin-angiotensin system (RAS) that is an essential player in the control of blood pressure and electrolyte balance. The final effect is to increase reabsorption of sodium and water, and thereafter increase blood pressure and excretion of potassium (K+). Besides, patients with COVID-19 often had gastrointestinal symptoms such as diarrhea and vomiting Early studies proved that high percentage of COVID-19 patient were presented with electrolyte disorders, including sodium, potassium, chloride and calcium abnormalities. Such electrolyte disturbances have important implications not only for patient management but also for identifying potential pathophysiologic mechanisms underlying COVID-19 that could drive novel therapeutic opportunities
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | electrolytes | measuring level of electrolytes |
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2021-08-01
- Completion
- 2021-10-30
- First posted
- 2020-09-07
- Last updated
- 2021-11-23
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04539834. Inclusion in this directory is not an endorsement.